The Generative Brain

Fulgent Genetics, Inc.

Fulgent Genetics, Inc. is a Delaware company founded in 2011 and listed on NASDAQ as FLGT since September 2016, now headquartered at 4399 Santa Anita Avenue, El Monte, California, and led by founder Ming Hsieh as Chairman and CEO. It runs a laboratory services business and a therapeutic development arm, Fulgent Pharma, and reported 2025 revenue of USD 322.7 million. For prion disease it lists two PRNP single gene NGS tests with deletion and duplication analysis in the NCBI GTR, plus a separate PRNP repeat expansion test by repeat primed PCR for the octapeptide repeat region, which the sequencing test does not cover. Its El Monte laboratory holds CLIA, CAP and New York State credentials. Prices and international ordering rules were not found. Information only.

Key facts

  • Delaware corporation founded in 2011; principal executive office at 4399 Santa Anita Avenue, El Monte, California 91731.
  • Listed on the NASDAQ Global Market as FLGT on 29 September 2016 at USD 9.00 per share; the company was then based in Temple City, California.
  • Ming Hsieh is Chairman of the Board and Chief Executive Officer and Paul Kim is Chief Financial Officer, as named in the results release of 27 February 2026.
  • Two businesses: laboratory services (anatomic pathology, precision diagnostics, BioPharma services and the Picture telemedicine platform) and therapeutic development through Fulgent Pharma, whose oncology candidates FID-007 and FID-022 were in Phase 2 and Phase 1.
  • 2025 revenue was USD 322.7 million, up 14 percent, with a GAAP loss of USD 60.5 million and about USD 705.5 million in cash and investments; 2026 revenue guidance is about USD 350 million.
  • Second quarter 2026 revenue was USD 85.4 million, against USD 81.8 million a year earlier.
  • CLIA certified, CAP accredited laboratories in California, Texas, Georgia, Massachusetts and Arizona plus a laboratory in Australia; operations in China are reported, and India was not mentioned in the 10-K text read.
  • The El Monte laboratory behind the PRNP tests lists CLIA 05D2043189, CAP 8042697 and New York PFI 9283, plus Maryland, California, Rhode Island and Pennsylvania licences.
  • GTR records GTR000566062 (Prion Disease, PRNP Single Gene Test) and GTR000518242 (PRNP Single Gene) both use NGS of the full coding region with deletion and duplication analysis, covering inherited Creutzfeldt-Jakob disease, fatal familial insomnia and Gerstmann-Straussler-Scheinker syndrome.
  • Accepted specimens for the PRNP single gene test include peripheral blood, saliva, buccal swab, isolated DNA and several tissue types.
  • The single gene test page states that sequencing does not cover the octapeptide repeat region, with a 2 to 3 week turnaround; suspected deletions or duplications are confirmed by qPCR or MLPA.
  • A separate PRNP Repeat Expansion test uses repeat primed PCR for octapeptide repeat variants, with a 2 week turnaround and rush and prenatal options; it excludes sequencing and copy number analysis unless requested.
  • A GTR search for PRNP plus Fulgent returned four records and no separate record for the repeat expansion test.
  • The 10-K says the Picture platform lets consumers initiate testing with clinical support, while laboratory results are interpreted by licensed physicians; whether PRNP tests can be ordered through Picture is not stated.
  • No list price is published for either PRNP test: both pages give cost as "Call for details" (read in full on 2026-10-31; they had returned HTTP 403 to automated fetch on 2026-10-16).
  • In GTR, Fulgent is one of several labs listing PRNP, alongside Labcorp Genetics, Blueprint Genetics, CeGaT and DNA Labs India.

Timeline

  1. 2011Fulgent Genetics founded.
  2. 2016IPO on NASDAQ as FLGT at USD 9.00 per share.
  3. 2025Acquisition of ANP Technologies, Inc. completed.
  4. 2025Agreement to acquire Bako Diagnostics and StrataDx announced.
  5. 2026Full year 2025 results reported: revenue USD 322.7 million.
  6. 2026Bako Diagnostics assets and StrataDx acquisition completed for about USD 56.9 million in cash.
  7. 2026Form 10-Q for the second quarter of 2026 filed, with revenue of USD 85.4 million.
  8. 2026Fulgent PRNP test pages return HTTP 403 to automated fetch; details rest on search excerpts.
Sources for this page